Efavirenz, lamivudine, and tenofovir and Fluoxetine interaction
Efavirenz, lamivudine, and tenofovir and Fluoxetine: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Efavirenz, lamivudine, and tenofovir (SYMFI) label · effective 2019-10-15
QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval.
Antidepressants: Bupropion ↓ bupropion Increases in bupropion dosage should be guided by clinical response.
From the Fluoxetine (Prozac) label · effective 2026-01-08
Additionally, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of several substrates for this enzyme, including astemizole, cisapride, and midazolam.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.